Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase

Eric R. Siemers, Robert A. Dean, Stuart Friedrich, Lisa Ferguson-Sells, Celedon Gonzales, Martin Farlow, Patrick C. May

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

OBJECTIVES: γ-Secretase inhibitors may be useful as disease-modifying drugs for the treatment of Alzheimer disease. LY450139 is a γ-secretase inhibitor currently in clinical development, with doses being optimized through the use of biomarkers. METHODS: To further characterize biomarker responses to LY450139, single oral doses of 60, 100, or 140 mg were administered to volunteers without neuropsychiatric disease. Extensive safety assessments were obtained along with measures of changes in amyloid-β (Aβ) in plasma and cerebrospinal fluid (CSF). A measure of the change in plasma Aβ1-40 was derived (area above the curve), which was determined by both the magnitude and duration of Aβ1-40 reduction. RESULTS: A total of 31 subjects (ages 49-53 years, 19 men) were enrolled. With the possible exception of headache, no clinically significant adverse events or laboratory changes were observed. A dose-proportional increase in drug exposure was present in plasma and in CSF. A dose-dependent change in plasma Aβ1-40 area above the curve was also demonstrated. Using the 140-mg dose, a maximum 72.6% reduction in plasma Aβ1-40 was demonstrated that did not return to baseline for more than 12 hours. Cerebrospinal fluid concentrations of Aβ were unchanged 4 hours after drug administration. CONCLUSIONS: These data show that single doses of LY450139 up to 140 mg are accompanied by a dose-dependent plasma Aβ response. No response in CSF Aβ was apparent 4 hours after dosing.

Original languageEnglish
Pages (from-to)317-325
Number of pages9
JournalClinical Neuropharmacology
Volume30
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Amyloid Precursor Protein Secretases
Amyloid
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Cerebrospinal Fluid
Safety
Biomarkers
Pharmaceutical Preparations
Headache
Inhibition (Psychology)
Volunteers
Alzheimer Disease

Keywords

  • Alzheimer disease
  • Amyloid-beta
  • Gamma-secretase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase. / Siemers, Eric R.; Dean, Robert A.; Friedrich, Stuart; Ferguson-Sells, Lisa; Gonzales, Celedon; Farlow, Martin; May, Patrick C.

In: Clinical Neuropharmacology, Vol. 30, No. 6, 11.2007, p. 317-325.

Research output: Contribution to journalArticle

Siemers, Eric R. ; Dean, Robert A. ; Friedrich, Stuart ; Ferguson-Sells, Lisa ; Gonzales, Celedon ; Farlow, Martin ; May, Patrick C. / Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase. In: Clinical Neuropharmacology. 2007 ; Vol. 30, No. 6. pp. 317-325.
@article{8a846ed5232b43ea839f5cb582c96bc6,
title = "Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase",
abstract = "OBJECTIVES: γ-Secretase inhibitors may be useful as disease-modifying drugs for the treatment of Alzheimer disease. LY450139 is a γ-secretase inhibitor currently in clinical development, with doses being optimized through the use of biomarkers. METHODS: To further characterize biomarker responses to LY450139, single oral doses of 60, 100, or 140 mg were administered to volunteers without neuropsychiatric disease. Extensive safety assessments were obtained along with measures of changes in amyloid-β (Aβ) in plasma and cerebrospinal fluid (CSF). A measure of the change in plasma Aβ1-40 was derived (area above the curve), which was determined by both the magnitude and duration of Aβ1-40 reduction. RESULTS: A total of 31 subjects (ages 49-53 years, 19 men) were enrolled. With the possible exception of headache, no clinically significant adverse events or laboratory changes were observed. A dose-proportional increase in drug exposure was present in plasma and in CSF. A dose-dependent change in plasma Aβ1-40 area above the curve was also demonstrated. Using the 140-mg dose, a maximum 72.6{\%} reduction in plasma Aβ1-40 was demonstrated that did not return to baseline for more than 12 hours. Cerebrospinal fluid concentrations of Aβ were unchanged 4 hours after drug administration. CONCLUSIONS: These data show that single doses of LY450139 up to 140 mg are accompanied by a dose-dependent plasma Aβ response. No response in CSF Aβ was apparent 4 hours after dosing.",
keywords = "Alzheimer disease, Amyloid-beta, Gamma-secretase inhibitors",
author = "Siemers, {Eric R.} and Dean, {Robert A.} and Stuart Friedrich and Lisa Ferguson-Sells and Celedon Gonzales and Martin Farlow and May, {Patrick C.}",
year = "2007",
month = "11",
doi = "10.1097/WNF.0b013e31805b7660",
language = "English",
volume = "30",
pages = "317--325",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase

AU - Siemers, Eric R.

AU - Dean, Robert A.

AU - Friedrich, Stuart

AU - Ferguson-Sells, Lisa

AU - Gonzales, Celedon

AU - Farlow, Martin

AU - May, Patrick C.

PY - 2007/11

Y1 - 2007/11

N2 - OBJECTIVES: γ-Secretase inhibitors may be useful as disease-modifying drugs for the treatment of Alzheimer disease. LY450139 is a γ-secretase inhibitor currently in clinical development, with doses being optimized through the use of biomarkers. METHODS: To further characterize biomarker responses to LY450139, single oral doses of 60, 100, or 140 mg were administered to volunteers without neuropsychiatric disease. Extensive safety assessments were obtained along with measures of changes in amyloid-β (Aβ) in plasma and cerebrospinal fluid (CSF). A measure of the change in plasma Aβ1-40 was derived (area above the curve), which was determined by both the magnitude and duration of Aβ1-40 reduction. RESULTS: A total of 31 subjects (ages 49-53 years, 19 men) were enrolled. With the possible exception of headache, no clinically significant adverse events or laboratory changes were observed. A dose-proportional increase in drug exposure was present in plasma and in CSF. A dose-dependent change in plasma Aβ1-40 area above the curve was also demonstrated. Using the 140-mg dose, a maximum 72.6% reduction in plasma Aβ1-40 was demonstrated that did not return to baseline for more than 12 hours. Cerebrospinal fluid concentrations of Aβ were unchanged 4 hours after drug administration. CONCLUSIONS: These data show that single doses of LY450139 up to 140 mg are accompanied by a dose-dependent plasma Aβ response. No response in CSF Aβ was apparent 4 hours after dosing.

AB - OBJECTIVES: γ-Secretase inhibitors may be useful as disease-modifying drugs for the treatment of Alzheimer disease. LY450139 is a γ-secretase inhibitor currently in clinical development, with doses being optimized through the use of biomarkers. METHODS: To further characterize biomarker responses to LY450139, single oral doses of 60, 100, or 140 mg were administered to volunteers without neuropsychiatric disease. Extensive safety assessments were obtained along with measures of changes in amyloid-β (Aβ) in plasma and cerebrospinal fluid (CSF). A measure of the change in plasma Aβ1-40 was derived (area above the curve), which was determined by both the magnitude and duration of Aβ1-40 reduction. RESULTS: A total of 31 subjects (ages 49-53 years, 19 men) were enrolled. With the possible exception of headache, no clinically significant adverse events or laboratory changes were observed. A dose-proportional increase in drug exposure was present in plasma and in CSF. A dose-dependent change in plasma Aβ1-40 area above the curve was also demonstrated. Using the 140-mg dose, a maximum 72.6% reduction in plasma Aβ1-40 was demonstrated that did not return to baseline for more than 12 hours. Cerebrospinal fluid concentrations of Aβ were unchanged 4 hours after drug administration. CONCLUSIONS: These data show that single doses of LY450139 up to 140 mg are accompanied by a dose-dependent plasma Aβ response. No response in CSF Aβ was apparent 4 hours after dosing.

KW - Alzheimer disease

KW - Amyloid-beta

KW - Gamma-secretase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=37349072443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349072443&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e31805b7660

DO - 10.1097/WNF.0b013e31805b7660

M3 - Article

VL - 30

SP - 317

EP - 325

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 6

ER -